Search results for "asm"

showing 10 items of 16598 documents

Analysis of nucleophosmin–anaplastic lymphoma kinase (NPM‐ALK)‐reactive CD8+ T cell responses in children with NPM‐ALK+ anaplastic large cell lymphoma

2016

Summary Cellular immune responses against the oncoantigen anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) have been detected using peptide-based approaches in individuals preselected for human leucocyte antigen (HLA)-A*02:01. In this study, we aimed to evaluate nucleophosmin (NPM)-ALK-specific CD8+ T cell responses in ALCL patients ensuring endogenous peptide processing of ALK antigens and avoiding HLA preselection. We also examined the HLA class I restriction of ALK-specific CD8+ T cells. Autologous dendritic cells (DCs) transfected with in-vitro-transcribed RNA (IVT-RNA) encoding NPM–ALK were used as antigen-presenting cells for T cell …

0301 basic medicineAdolescentT cellImmunologyHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesLymphocyte ActivationAntibodiesCell Line03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmT-Lymphocyte Subsetshemic and lymphatic diseasesmedicineImmunology and AllergyAnaplastic lymphoma kinaseCytotoxic T cellAnimalsHumansChildAnaplastic large-cell lymphomaAllelesintegumentary systemELISPOTHistocompatibility Antigens Class IInfantOriginal ArticlesProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologymedicine.anatomical_structureChild PreschoolImmunologyCancer researchLymphoma Large-Cell AnaplasticCD8030215 immunology
researchProduct

Tumor-priming converts NK cells to memory-like NK cells

2017

Fascinating earlier evidence suggests an intrinsic capacity of human natural killer (NK) cells to acquire adaptive immune features in the context of cytomegalovirus (CMV) infection or pro-inflammatory cytokine stimulation. Since the role of memory NK cells in cancer has so far remained elusive and adoptive NK cell transfer in relapsing pediatric acute B cell precursor leukemia (BCP-ALL) patients awaits improvement, we asked the question whether tumor-priming could promote the generation of memory NK cells with enhanced graft-vs.-leukemia (GvL) reactivity. Here, we provide substantial evidence that priming of naive human NK cells with pediatric acute B cell leukemia or acute myeloid leukemia…

0301 basic medicineAdoptive cell transferImmunology03 medical and health sciencesInterleukin 21NK-92childrenmedicineImmunology and Allergyddc:610B celladoptive cell transferRC254-282Original ResearchLymphokine-activated killer cellnatural killer cellsbiologyJanus kinase 3Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607030104 developmental biologymedicine.anatomical_structureacute b cell precursor leukemiaOncologyPerforinImmunologyInterleukin 12biology.proteinImmunologic diseases. AllergyOncoImmunology
researchProduct

Mutanome directed cancer immunotherapy

2015

Somatic mutations are important drivers of cancer development. Accumulating evidence suggests that a significant subset of mutations result in neo-epitopes recognized by autologous T cells and thus may constitute the Achilles' heel of tumor cells. T cells directed against mutations have been shown to have a key role in clinical efficacy of potent cancer immunotherapy modalities, such as adoptive transfer of autologous tumor infiltrating lymphocytes and immune checkpoint inhibitors. Whereas these findings strengthen the idea of a prominent role of neo-epitopes in tumor rejection, the systematic therapeutic exploitation of mutations was hampered until recently by the uniqueness of the reperto…

0301 basic medicineAdoptive cell transferSomatic cellT-Lymphocytesmedicine.medical_treatmentImmune checkpoint inhibitorsImmunology03 medical and health sciences0302 clinical medicineCancer immunotherapyAntigens NeoplasmNeoplasmsAnimalsHumansImmunology and AllergyMedicineClinical efficacybusiness.industryAutologous T-cellsImmune recognition030104 developmental biology030220 oncology & carcinogenesisTumor rejectionMutationImmunologyImmunotherapybusiness
researchProduct

γδ cells and tumor microenvironment: A helpful or a dangerous liason?

2017

Abstract γδ T cells are a subset of T lymphocytes that have been implicated in immunosurveillance against infections and tumors. γδ T cells are endowed with antitumor activities, and hence several γδ T cell-based small-scale clinical trials have been conducted either by in vivo activation by intravenous administration of aminobiphosphonates or by adoptive transfer of in vitro expanded γδ T cells. Although both these strategies have yielded promising results, there are a number of limitations associated with each of them which, if overcome may help to further improve efficacy. One of the most important limits is the possible polarization of tumor-infiltrating γδ T cells toward different γδ T…

0301 basic medicineAdoptive cell transferT cellmedicine.medical_treatmentT-LymphocytesImmunologyPopulationBiology03 medical and health sciencesCancer immunotherapytumor-infiltrating lymphocyteNeoplasmsmedicineTumor MicroenvironmentImmunology and AllergyHumanseducationγδ T cellTumor microenvironmenteducation.field_of_studyTumor-infiltrating lymphocytesReceptors Antigen T-Cell gamma-deltaCell BiologyIn vitroImmunosurveillance030104 developmental biologymedicine.anatomical_structureT-LymphocyteCancer researchNeoplasmtumor microenviromentHumanJournal of leukocyte biology
researchProduct

γδ cell-based immunotherapy for cancer.

2019

Introduction: Cancer immunotherapy relies on the development of an efficient and long-lasting anti-tumor response, generally mediated by cytotoxic T cells. gamma delta T cells possess distinctive features that justify their use in cancer immunotherapy. Areas covered: Here we will review our current knowledge on the functions of human gamma delta T cells that may be relevant in tumor immunity and the most recent advances in our understanding of how these functions are regulated in the tumor microenvironment. We will also discuss the major achievements and limitations of gamma delta T cell-based immunotherapy of cancer. Expert opinion: Several small-scale clinical trials have been conducted i…

0301 basic medicineAdoptive cell transfergamma delta T celladoptive transfermedicine.medical_treatmentT cellClinical BiochemistryImmunotherapy Adoptive03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsDrug DiscoveryAnimalsHumansMedicineCytotoxic T cellcancertumor microenvironmentIntraepithelial LymphocytesPharmacologyTumor microenvironmentbusiness.industryCancerImmunotherapymedicine.diseaseClinical trial030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisCancer researchcytotoxicitybusiness
researchProduct

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

2019

Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. Methods: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. Th…

0301 basic medicineAdultCancer ResearchSkin NeoplasmsBioinformaticsBone NeoplasmsBreast Neoplasmsmedicine.disease_causeMetastatic tumours03 medical and health sciences0302 clinical medicineBreast cancerBreast cancermedicineBiomarkers TumorHumansProspective StudiesPAM50AgedAged 80 and overMutationIntrinsic subtypebusiness.industryHuman epidermal growth factorBrain NeoplasmsClonal architectureHigh-Throughput Nucleotide SequencingClonal remodellingMiddle Agedmedicine.diseasePrognosisGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisCancer cellMutationCancer researchFemaleNeoplasm Recurrence LocalClinical subtypeHeterogeneitybusinessHormoneFollow-Up Studies
researchProduct

Factors Affecting Sexual Function and Body Image of Early-Stage Breast Cancer Survivors in Poland: A Short-Term Observation

2019

Abstract Introduction Knowing the important factors influencing sexual function and body image might facilitate the recovery process of breast cancer survivors. Surgery type, relationship quality, and partner support might be modified to create a space for psychosexual intervention. Patients and Methods This retrospective questionnaire-based study was performed on 128 women aged 18 to 65 years who were free of disease at time of study entry and who underwent surgical treatment for breast cancer. Diagnostic and Statistical Manual of Mental Disorders criteria were used to assessed female sexual dysfunction (FSD). Changes in Sexual Functioning Questionnaire (CSFQ) were used to measure sexual f…

0301 basic medicineAdultCancer Researchmedicine.medical_specialtyAdolescentbody imagebreast cancer survivorsmedicine.medical_treatmentMammaplastySexual BehaviorFemale sexual dysfunctionBreast NeoplasmsMastectomy Segmental03 medical and health sciencesYoung Adultdeterminant factors0302 clinical medicineBreast cancersurgery timeQuality of lifeCancer SurvivorsInternal medicineMedicineHumansMastectomyAgedRetrospective Studiesbusiness.industryOdds ratioMiddle Agedmedicine.disease030104 developmental biologySexual dysfunctionOncologysexual dysfunction030220 oncology & carcinogenesisQuality of LifeAnxietyFemalePolandmedicine.symptombusinessSexual functionMastectomyClinical Breast Cancer
researchProduct

Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

2020

Background: Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol. Materials and methods: We combined metabolomics, exosome circulating miRNAs and flow cytometry experimental approaches in TNBC patients at diagnosis with immunohistochemistry in needle biopsy tumours to generate NAC-response predictive models. We also co-cultured and studied crosstalk between isolated patient…

0301 basic medicineAdultCancer Researchmedicine.medical_treatmentTriple Negative Breast NeoplasmsExosomesExosome03 medical and health sciences0302 clinical medicineImmune systemBreast cancerTriple-negative breast cancermicroRNABiomarkers TumorImmune ToleranceMedicineHumansIndoleamine-Pyrrole 23-DioxygenaseMetabolomicsProspective StudiesLiquid biopsyTriple-negative breast cancerCells CulturedAgedChemotherapybusiness.industryLiquid BiopsyTryptophanImmunosuppressionMiddle Agedmedicine.diseaseImmunohistochemistryCoculture TechniquesNeoadjuvant TherapyMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchFemaleNAC responsebusinessImmunosuppressionEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Epithelial-mesenchymal transition: a new target in anticancer drug discovery

2016

The conversion of cells with an epithelial phenotype into cells with a mesenchymal phenotype, referred to as epithelial-mesenchymal transition, is a critical process for embryonic development that also occurs in adult life, particularly during tumour progression. Tumour cells undergoing epithelial-mesenchymal transition acquire the capacity to disarm the body's antitumour defences, resist apoptosis and anticancer drugs, disseminate throughout the organism, and act as a reservoir that replenishes and expands the tumour cell population. Epithelial-mesenchymal transition is therefore becoming a target of prime interest for anticancer therapy. Here, we discuss the screening and classification o…

0301 basic medicineAdultEpithelial-Mesenchymal TransitionCellPopulationAntineoplastic AgentsPharmacologyBiology03 medical and health sciences0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALENeoplasmsDrug DiscoverymedicineHumanscancerEpithelial–mesenchymal transitioneducationAdult; Antineoplastic Agents; Epithelial-Mesenchymal Transition; Humans; Neoplasms; Drug Discovery; Pharmacology; Drug Discovery3003 Pharmaceutical SciencePharmacologyeducation.field_of_studyTransition (genetics)Drug discoveryDrug Discovery3003 Pharmaceutical ScienceGeneral MedicineAnticancer drugEMT target therapy chemoresistance030104 developmental biologymedicine.anatomical_structureDrug developmentApoptosis030220 oncology & carcinogenesisCancer research
researchProduct